About a thousand genes in the human genome encode for membrane transporters. Among these, several solute carrier proteins (SLCs), representing the largest group of transporters, are still orphan and lack functional characterization. We reasoned that assessing genetic interactions among SLCs may be an efficient way to obtain functional information allowing their deorphanization. Here we describe a network of strong genetic interactions indicating a contribution to mitochondrial respiration and redox metabolism for SLC25A51/MCART1, an uncharacterized member of the SLC25 family of transporters. Through a combination of metabolomics, genomics and genetics approaches, we demonstrate a role for SLC25A51 as enabler of mitochondrial import of NAD, showcasing the potential of genetic interaction-driven functional gene deorphanization.
Transmembrane transporters are key contributors to the energetic and metabolic needs of a cell. The largest human family of transporters is composed of Solute Carriers (SLCs), a diverse set of transmembrane proteins consisting of more than 400 members1. SLCs can be found on both the plasma membrane and in intracellular organelles, where they control the uptake and release of all major classes of biologically active molecules. Although several prominent members of the family have been the focus of extensive research, a large proportion of them remains uncharacterized2,3, making this one of the most asymmetrically studied human protein families4.
Genetic interactions offer a powerful way to infer gene function by a guilt-by-association principle5,6, with negatively interacting pairs often sharing functional overlap. Positive interactions, on the other hand, can reflect regulatory connections or participation in the same protein complex. Fundamental studies in model organisms have systematically expanded our understanding of genetic regulatory networks and functionally annotated orphan genes6,7 and recent technological developments, in particular the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based approaches, made now possible to tackle systematic mapping of genetic interaction landscapes in human cells8,9,10,11,12.
To gain insight into the interplay and functional redundancy among SLCs, we have been systematically characterizing their genetic interaction landscape in the human cell line HAP113. This was achieved by combining a panel of isogenic cell lines each lacking 1 of 141 highly expressed, non-essential SLCs14,15 with a CRISPR/Cas9 library targeting 390 human SLC genes16. Genetic interactions were calculated by comparing the cellular fitness, approximated by the corresponding single guide RNAs depletion in wild-type (wt) or SLC-deficient cells, of single and double knockout (KO) combinations13. The resulting dataset, comprising more than 55,000 SLC–SLC combinations at multiple time points, provides a valuable resource for the systematic generation of testable hypotheses for orphan SLCs, as exemplified below.
Approximately 60 SLCs are expressed in the mitochondria3. Most of these are members of the SLC25 subfamily, which currently includes 53 transporters17,18. Although several mitochondrial transporters remain orphans, our growing understanding of cellular and mitochondrial metabolism leads us to postulate the existence of yet uncharacterized transporters for specific metabolites19. Among these, the presence and nature of a mammalian mitochondrial nicotinamide adenine dinucleotide, NAD(H), carrier has been controversial20. NAD(H) controls cellular redox state and is a required cofactor for key metabolic pathways such as glycolysis, the tricarboxylic acid (TCA) cycle and one carbon metabolism. Moreover, NAD(H) acts as a substrate for non-redox reactions including deacetylation by sirtuins and post translation modifications by poly(ADP-ribose) polymerases20,21. Previous studies suggested that NAD(H) might be synthetized in the mitochondria from precursors such as nicotinamide22 or nicotinamide mononucleotide (NMN)23. However, recent studies demonstrated that mitochondria can import NAD+24, and that the cytosolic NAD(H) levels affect the mitochondrial pool25, suggesting the presence of a transporter responsible for NAD + compartmentalization20. Moreover, mitochondrial NAD + transporters have been identified in yeast and plants26,27 but no functional ortholog has been yet identified in humans28. Here we show, using an epistasis-driven approach, that the orphan solute carrier SLC25A51 controls the levels of mitochondrial NAD(H) and is the functional ortholog of the yeast mitochondrial NAD+ transporter, therefore identifying it, to the best of our knowledge, as a bona fide human mitochondrial NAD+ transporter.
A genetic interaction network for the orphan gene SLC25A51 suggests a role in redox and one carbon metabolism
Within the SLC genetic interaction dataset (Fig. 1a)13, the strongest interactions involved a small network of transporters centered around the orphan gene SLC25A51, encoding for Mitochondrial Carrier Triple Repeat 1 (MCART1, Fig. 1b). We observed a strong negative interaction of SLC25A51 with the main glucose transporter expressed at the plasma membrane, SLC2A1/GLUT1, a major regulator of glycolytic metabolism29, suggesting a potential role of SLC25A51 in cellular energetics. Moreover, we observed negative interactions with the methionine transporter genes SLC7A5 and SLC43A2, as well as the paralog SLC43A3, which has been reported to transport nucleosides and play a role in the purine salvage pathway30. These connections, together with the strong positive interactions observed with SLC7A11 and SLC3A2, encoding the subunits of the heterodimeric glutamate/cystine transporter xCT31 and an important regulator of the methionine cycle and of glutathione production, suggested a potential link of SLC25A51 with one carbon and redox metabolism.
SLC25A51 is a member of the SLC25 family of mitochondrial carriers, showing close homology to the paralogs SLC25A52 and, to a lesser extent, SLC25A5332. Similar to the other family members, SLC25A51 is predicted to contain six transmembrane regions, with its N and C termini exposed towards the mitochondrial intermembrane space (Supplementary Fig. 1a)33. Functional genomics studies showed that loss of SLC25A51 can have a strong effect on cell growth34, although it is not strictly essential in HAP1 cells15,16. Interestingly, and consistent with its effect on cellular fitness, <1 in 2000 individuals carry a putative deleterious mutation in SLC25A51, suggesting it is one of the most functionally conserved SLCs across humans35. Analysis of transcriptomics data across healthy tissues further showed that this transporter, but not its close paralog SLC25A52, is widely and robustly expressed (Supplementary Fig. 1b)36, consistent with SLC25A51 playing an important function conserved across tissues.
Interestingly, we further observed a similar set of genetic interactions for SLC25A51 and SLC25A3 (Fig. 1b), a phosphate mitochondrial transporter for which a key role in oxidative phosphorylation, calcium handling, copper homeostasis, and biogenesis of complex IV of the electron transport chain has been reported37,38, consistent with their similar genetic interaction profiles across the full dataset (Fig. 1a). Both genes showed negative interactions with SLC2A1 and SLC43A2, as well as positive interactions with SLC7A11 and SLC3A2, suggesting the loss of these two genes had similar effects on glycolysis and one carbon metabolism. Importantly, we further observed SLC25A51-specific negative interactions with two additional members of the SLC25 family, the paralog SLC25A53 and the gene for the putative folate/FAD transporter SLC25A32 (Fig. 1b)39. Although no function has been assigned to SLC25A53 yet, the interaction to SLC25A32 pointed to a possible involvement of SLC25A51 in mitochondrial cofactor transport. Overall, analysis of SLC–SLC genetic interactions resulted in the identification of cellular processes associated with loss-of-function of the broadly expressed SLC25A51 transporter, including one carbon and redox metabolism.
SLC25A51-deficient cells have impaired mitochondrial respiration
Prompted by the observed genetic profile similarity between the mitochondrial phosphate carrier SLC25A3 and SLC25A51, and the predicted effects on cellular energetics, we tested whether SLC25A51-deficient cells showed a defect in mitochondrial respiration. When measuring Oxygen Consumption Rate (OCR), SLC25A51-deficient cells, but not cells lacking the glutamate/aspartate carrier SLC25A13, showed a loss of mitochondrial respiration comparable to SLC25A3-deficient cells (Fig. 2a). Ectopic expression of SLC25A51 confirmed its predicted localization at the mitochondria, as assessed by co-staining with the organelle marker apoptosis-inducing factor (AIF, Supplementary Fig. 2a), similar to the well-characterized mitochondrial transporter SLC25A3. Importantly, expression of SLC25A51, but not SLC25A3, restored mitochondrial respiration, suggesting that the two transporters affected OCR in non-redundant ways, likely through the transport of different substrates (Fig. 2a, b).
Co-essentiality analysis suggests a role for SLC25A51 in mitochondrial energetics
If indeed SLC25A51 and SLC25A3 encoded for complementary, non-redundant functions, then they should display correlations in a genetic co-dependency analysis40, as genes with related functions will have similar essentiality profiles across cell lines. Consistent with our genetic interaction and OCR results, a co-dependency analysis based on the profile of essentiality of SLC25A51 across the DepMap dataset41 revealed SLC25A3 as the most correlated SLC, as well as high correlation to genes encoding subunits of the electron transport chain, ATP synthase and the mitochondrial ribosome (Fig. 3a), supporting a possible role of SLC25A51 in enabling mitochondrial respiration. Among the other, highly correlating SLCs, we observed several mitochondrial cofactor transporters, including the SAM transporter SLC25A2642, the thiamine transporter SLC25A1943, and the folate/FAD transporter SLC25A32 (Fig. 3a). Interestingly, analysis of the co-dependencies specific to SLC25A51 and not SLC25A3 highlighted a similarity to mutations of pyruvate dehydrogenase and citrate synthase (Supplementary Fig. 2b), suggesting that loss of SLC25A51 mimicked the loss of enzymes acting at the early stages of the TCA cycle, several of which rely on NAD, thiamine, and CoA for their function. Overall, co-essentiality analysis further supported an involvement of SLC25A51 in mitochondrial energetics, possibly through transport of a key cofactor.
Comparative whole-cell and mitochondrial targeted metabolomics identifies key metabolites affected by SLC25A51 loss
To test whether loss of SLC25A51 function was consistent with the functional annotation proposed by its SLC genetic interaction network and the co-essentiality analysis, we characterized the metabolic changes in cells lacking either SLC25A51 or SLC25A3 compared to wt cells by measuring the abundances of a panel of 194 metabolites by liquid chromatography–tandem mass spectrometry (LC-MS/MS) (Fig. 4a–c and Supplementary Fig. 2c). We observed a similar pattern of changes, including depletion of riboflavin, purine nucleotides AMP and IMP, and enrichment of their precursor AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), as well as increased levels of metabolites associated to glutathione metabolism, pointing to a defect in one carbon and redox metabolism (Fig. 4b). This is consistent with the previously mentioned negative interactions of SLC25A51 with methionine transporters, the putative mitochondrial folate/FAD transporter SLC25A32, as well as the purine transporter SLC43A3 (Fig. 1b). Interestingly, comparison of changes in metabolites between SLC25A51- and SLC25A3-deficient cells showed stronger depletion of TCA cycle intermediates, including citrate, aconitate and cis-aconitate, isocitrate and succinate, in SLC25A51 knockouts (Fig. 4d), suggesting that comparison of metabolic profiles from whole cells lacking functionally related genes can provide insights into specifically affected processes consistent with genetic analyses.
Based on the evidence so far accumulated, we reasoned that SLC25A51 could provide a small molecule or cofactor involved with both the early stages of the TCA cycle as well as the assembly/functioning of the electron transport chain (ETC) (Fig. 5a). Among these cofactors and vitamins, NAD was the only significantly depleted molecule in SLC25A51-deficient cells vs. SLC25A3-deficient ones (Fig. 4a–d), leading us to hypothesize that SLC25A51 could be involved in the uptake of NAD(H) or its precursors. Consistent with these results, NAD(H) levels were reduced in SLC25A51-deficient cells compared to SLC25A3 knockouts, when measured by a luminescence-based assay (Supplementary Fig. 2c). To further investigate this possibility, we measured metabolite abundance in samples enriched in mitochondria from wt or SLC25A51-deficient cells (Fig. 5b and Supplementary Fig. 2d). NAD was the most depleted metabolite in SLC25A51-deficient mitochondria, with several other TCA metabolites also being reduced. To further establish the effect of SLC25A51 on mitochondrial NAD levels, we measured NAD content in mitochondria from cells lacking SLC25A51, or KOs reconstituted with either mitoGFP, SLC25A51, or SLC25A3. Consistent with a role for SLC25A51 in NAD transport, this nucleotide was drastically depleted in ΔSLC25A51 cells, compared to wt (Fig. 5c). Importantly, overexpression of SLC25A51, but not mitoGFP or SLC25A3, restored the levels of NAD within the mitochondria (Fig. 5c). These findings therefore suggest that SLC25A51 affects multiple metabolic pathways by controlling the levels of mitochondrial NAD(H).
Complementation with the yeast NAD+ transporter restores mitochondrial respiration in SLC25A51-deficient cells
We then reasoned that, if SLC25A51 encoded a NAD(H) transporter function in human cells, the well-characterized Saccharomyces cerevisiae mitochondrial NAD+ transporters, Ndt1p and Ndt2p26, should be able to functionally rescue the respiration defect and reduced NAD levels observed in ΔSLC25A51 cells. Ectopic expression of NDT2 did not result in discernible expression in HAP1 ΔSLC25A51 cells, possibly reflecting its lower stability26 (Supplementary Fig. 1e). However, ectopic expression of yeast NDT1 resulted in a clear mitochondrial localization of the construct in SLC25A51-deficient cells and reversed the mitochondrial respiration defect of the SLC25A51-deficient cells (Fig. 6a, b and Supplementary Fig. 1e).
Accordingly, expression of human SLC25A51 in the Δndt1Δndt2 S. cerevisiae strain almost completely rescued the growth defect of the mutant in a minimal medium supplemented with ethanol and partially restored the levels of mitochondrial NAD+ (Fig. 6c, d). In summary, our results show that SLC25A51 is the functional homolog of the well-characterized yeast mitochondrial NAD+ transporter Ndt1p.
The question of what is the main source of mammalian mitochondrial NAD(H), a key molecule in several biochemical and signaling pathways, has been a matter of debate, with several reports suggesting NAD+ is synthetized within the organelle from precursors such as NMN or nicotinamide due to its inability to cross the mitochondrial membrane22,23. In contrast, recent studies provided evidence suggesting that NAD+ is actively transported into mitochondria24, consistent with the observed interplay between its cytoplasmic and mitochondrial pools25. Despite the presence of mitochondrial NAD+ carriers in yeast and plants, the nature of the transporter involved has however remained elusive20,26,28, as none of their closest structural homologs have been demonstrated to affect mitochondrial NAD+ levels28. Here, starting from a network of genetic interactions among SLCs pinpointing a role for this gene in redox and one carbon metabolism, we show that loss of SLC25A51 dramatically impairs mitochondrial respiration and mimics the loss of activity of enzymes of the early steps of the TCA cycle. Through comparative targeted metabolomics approaches, we observed perturbed levels of TCA cycle metabolites and NAD(H) in whole-cell lysates from SLC25A51-deficient cells and observed drastically reduced levels of NAD(H) in mitochondria from the same cells. Finally, we showed that the yeast NAD+ transporter Ndtp1 and SLC25A51 can reciprocally complement their defective mitochondrial NAD+ levels, leading us to suggest that the previously orphan transporter SLC25A51 is required for NAD+ uptake in human mitochondria. While additional data, including transport assays with reconstituted recombinant protein, will be necessary to definitely prove the role of SLC25A51 as NAD+ transporter and fully define its substrate profile and transport mechanism, the multiple functional links here described convincingly converge on a functional annotation of SLC25A51 as an enabler of NAD+ accumulation in mitochondria. This annotation is corroborated by two recent publications44,45 providing complementary evidence, including metabolomics analyses and yeast complementation experiments, of SLC25A51 being the long-hypothesized mitochondrial NAD+ transporter in human cells. Further studies addressing the interplay between SLC25A51 and the close paralogs SLC25A52, which also showed the ability to transport NAD+44,45, and the orphan SLC25A53 are also expected to shed light on the physiological relevance and regulatory mechanisms of this SLC.
Despite the high degree of functional redundancy displayed by transporters46, we show here that informative patterns of genetic interactions can be systematically derived for this family, allowing the generation of testable hypotheses for the de-orphanization of poorly characterized SLCs. Of all approaches that we have used in the past, including proteomics47,48, drug resistance16,49, and cell biological readouts50,51, genetic interactions among SLC has the potential to be one of the most powerful, as data points contribute to construct the evidence. As in a puzzle with a limited set of pieces, if all components are evaluated, individual genes may become implicated by exclusion principles. The most severe limitation of this approach is the relatively small dimension of phenotypic space interrogated in our study: cellular fitness under a given set of growth conditions. However, in principle, the approach can be expanded to additional dimensions, by changing carbon source, or using a different read-out, such as expression of a marker gene or resistance to a specific stress. The focus on only SLC transporters, in contrast to genome-wide screens or all membrane proteins, represents at the same time a clear limitation but also a technical advantage. Genetic interactions of a larger number of genes, such as all genes in the human genome, still represents a formidable technical challenge as the number of cells analyzed and the depth of the sequencing required to obtain statistically meaningful data would elude the power of even a small consortium of laboratories. However, yet more efficient sequencing strategies, reliable robotics and robotics-compatible large cell culture incubators are likely to eventually allow to test complete genome vs. genome interactions. Meanwhile, the focus proposed here appears like a practical intermediate approach.
In conclusion, we believe that the experimental evidence obtained in this study highlights the power of using genetic interactions, and particularly the comparison of genetic interaction profiles across genes, as discovery catalyst for the functional annotation of orphan genes and SLCs in particular.
Cell lines and reagents
HAP1 cells (Haplogen Genomics) were grown in Iscove’s modified Dulbecco’s medium with 10% fetal bovine serum (FBS), 1% Pen/Strep. HEK293T (American Type Culture Collection) were grown in Dulbecco’s modfied Eagle’s medium with 10% FBS, 1% Pen/Strep (Gibco). The SLC-deficient clones (ΔSLC25A51_1927-10, ΔSLC25A51_1927-11, ΔSLC25A3_792_1, ΔSLC25A3_792_6, and ΔSLC25A13_789_6, renamed as ΔSLC25A51_1, ΔSLC25A51_2, ΔSLC25A3_1, ΔSLC25A3_2, and ΔSLC25A13_1, respectively) were obtained from Haplogen Genomics. Codon-optimized SLC25A51, SLC25A3 cDNAs, or mitoGFP cDNA sequences (the latter carrying the mitochondrial import sequence derived from subunit 8 of complex IV) were obtained from the ReSOLUTE consortium (https://re-solute.eu/). The yeast NAD+ transporters ndt1/yil006w and ndt2/yel006w were obtained from Horizon Discovery (catalog IDs YSC3867-202327426 and YSC3867-202326304, respectively). cDNAs were cloned into a modified pCW57.1 lentiviral vector (Addgene #41393) generated within the ReSOLUTE consortium and carrying a Strep-HA tag and blasticidin resistance.
Cells carrying inducible constructs were treated with 1 μg/ml doxycycline for 24 h before plating. To limit effects due to different doubling times across the cells lines tested, cells were seeded in 96-well plates at 40,000 cells/well on the same day of the experiment. Before measurement, medium was exchanged for XF Base Medium (Agilent 102353-100) containing glucose (10 mM), sodium pyruvate (1 mM), and l-glutamine (2 mM), and cells were incubated for 1 h at 37 °C. Measurements were carried out on a Seahorse XF96 (Agilent) with a MitoStress (Agilent, 103015-100) kit, following the manufacturer’s instructions. Oligomycin, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, and a mix of Rotenone and Antimycin A were injected at desired time points at a final concentration of 1, 1.5, and 0.6 μM, respectively. After measurement, the medium was removed, cells were lysed, and protein amount was determined by a Bradford Assay. Data were normalized to protein amount and analyzed with Seahorse Wave 2.6.1 (Agilent) and Prism v8 (Graph Pad).
Essentiality data were obtained from DepMap (version 19Q3). Pearson’s correlations were calculated between the essentiality profiles (determined by the Ceres score52) of each gene across the cell line panel tested.
Cells were plated at 0.8–0.9 × 106 cells/well in six-well plates in full media. After 24 h, the cells were gently washed with room temperature phosphate-buffered saline (PBS), transferred to ice and 1.5 ml of ice-cold 80:20 MeOH:H2O solution was added to each well. The cells were scraped and transferred to a pre-cooled Eppendorf tube, snap-freezed in liquid nitrogen and thawed in ice before being centrifuged at 16,000 × g for 10 min at 4 °C. Cell extracts were dried downs using a nitrogen evaporator. The dry residue was reconstituted in 50 µL of water. Ten microliters of sample extract was mixed with 10 µL of isotopically labeled internal standard mixture in high-performance liquid chromatography vial and used for LC-MS/MS analysis. A 1290 Infinity II UHPLC system (Agilent Technologies) coupled with a 6470 triple quadrupole mass spectrometer (Agilent Technologies) was used for the LC-MS/MS analysis. The chromatographic separation for samples was carried out on a ZORBAX RRHD Extend-C18, 2.1 × 150 mm, 1.8 µm analytical column (Agilent Technologies). The column was maintained at a temperature of 40 °C and 4 µL of sample was injected per run. The mobile phase A was 3% methanol (v/v), 10 mM tributylamine, 15 mM acetic acid in water, and mobile phase B was 10 mM tributylamine, 15 mM acetic acid in methanol. The gradient elution with a flow rate 0.25 mL/min was performed for a total time of 24 min. Afterward, a back flushing of the column using a 6port/2-position divert valve was carried out for 8 min using acetonitrile, followed by 8 min of column equilibration with 100% mobile phase A. The triple quadrupole mass spectrometer was operated in an electrospray ionization negative mode, spray voltage 2 kV, gas temperature 150 °C, gas flow 1.3 L/min, nebulizer 45 psi, sheath gas temperature 325 °C, and sheath gas flow 12 L/min. The metabolites of interest were detected using a dynamic Multiple Reaction Monitoring (MRM) mode. The MassHunter 10.0 software (Agilent Technologies) was used for the data processing. Ten-point linear calibration curves with internal standardization was constructed for the quantification of metabolites. Conditions were compared using Welch’s t-test, p-value was subsequently corrected for multiple testing according to the Benjamini and Hochberg procedure39. Pathway enrichment was performed testing significantly affected metabolites (p < 0.05) against the Small Molecule Pathway Database53 with MetaboAnalyst54.
Subcellular fractionation of mitochondria was performed with a protocol derived from ref. 55. Cells were homogenized in 2 ml of ice-cold mitochondrial enrichment buffer (200 mM Sucrose, 1 mM EDTA-Tris, 10 mMTris-MOPS pH 7.4) by using a Branson sonicator (30 s, Amplitude 10%, 05 s on/0.5 s off). The nuclear fraction was removed by centrifugation at 600 × g for 10 min at 4 °C. Mitochondrial fraction were pelleted from the supernatant by centrifugation at 10,000 × g for 15 min at 4 °C. The final mitochondrial pellet were subsequently washed with 500 µl of mitochondrial enrichment buffer (10,000 × g for 15 min at 4 °C) before being subjected to MeOH:H2O extraction and LC/MS analysis. Mitochondrial enrichment was confirmed by western blotting using antibodies against alpha-tubulin (DM1A, Abcam #7291, 1:5000) and VDAC (Abcam #15895, 1:1000).
The yeast strains used in all experiments were the wt BY4742 (MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0) and the isogenic Δndt1Δndt2 (BY4742 ndt1::KanMX ndt2::HphMX)26. The SLC25A51 CDS was cloned in the HindIII/BamHI restriction sites of the yeast expression vector pYES2 in which the inducible GAL1 promoter had been replaced with the constitutive TDH3 promoter and carried a V5-tag at its C terminus. For the initial propagation, yeast cells were grown in rich (YP) medium, containing 2% Bacto-peptone and 1% yeast extract, supplemented with 2% glucose. Growth complementation assays were carried out in YNB medium pH 4.5 supplemented with 2% EtOH and the appropriate auxotrophic nutrients. Mitochondria were isolated from cells grown in ethanol-supplemented YP until the early exponential phase (optical density between 1.0 and 1.5) was reached26. For the NAD+ HPLC analysis, nucleotides were extracted from mitochondria by addition of 1.2 M ice-cold perchloric acid followed by neutralization with 30% KOH. After centrifugation and filtration, supernatants were subjected to HPLC analysis using a Waters Alliance 2695 separation module (Waters, Milford, MA, USA) equipped with a Kinetex EVO C18 column (Phenomenex, 150 mm × 4.6 mm, 100 Å, 5 µm), coupled to a Waters 2996 UV detector set at at 254 nm. Separation was carried out at 25 °C using two mobile phases consisting of 20 mM phosphate buffer with 8 mM tetra-n-butyl-ammonium bisulfate (TBA) pH 6 (solvent A) and 50% acetonitrile (solvent B) at a flow rate of 0.7 ml/min. Solvent A was held for the first 12 min; then a linear gradient profile started reaching 10% B in 4 min and 20% B in further 4 min; then it was increased up to 40% in the following 2 min and finally was kept constant for the last 8 min of separation. The initial conditions were then restored in 15 min.
For the confocal imaging of HAP1 cells cells, high precision microscope cover glasses (Marienfeld) were coated with poly-l-lysine hydrobromide (p6282, Sigma-Aldrich) according to the manufacturer’s protocol. Cells were seeded onto cover glasses in normal growth medium and fixed in 4% formaldehyde solution (AppliChem) in PBS 1× after 24 h of incubation. Permeabilization and blocking of samples was performed in blocking solution (5% fetal calf serum, 0.3% Triton X-100 in PBS 1×) for 1 h rocking. Anti-HA Tag (Roche #11867423001) and anti-AIF (CST #5318) primary antibodies were diluted 1:500 in antibody dilution buffer (1% bovine serum albumin, 0.3% Triton X-100 in PBS 1×) and applied for 2 h at room temperature, rocking. Samples were washed three times in antibody dilution buffer and anti-rat Alexa Fluor 488 (Thermo Fischer Scientific #A11006) and anti-rabbit Alexa Fluor 594 (Thermo Fischer Scientific #A11012) secondary antibodies were applied 1 : 500 in antibody dilution buffer for 1 h at room temperature, rocking. After three times washing in antibody dilution buffer, nuclei were counterstained with 4′,6-diamidino-2-phenylindole 1:1000 in PBS 1×, for 10 min, rocking. Cover glasses were mounted onto microscopy slides using ProLong Gold (Thermo Fischer Scientific #P36934) antifade mountant. Image acquisition was performed on a confocal laser scanning microscope (Zeiss LSM 780, Carl Zeiss AG), equipped with an Airyscan detector using ZEN black 2.3 (Carl Zeiss AG).
NAD/NADH and ATP measurements
For luminescence-based assays, 10,000 HAP1 cells/well were plated in a 96-well plate in triplicates. After 6 h, ATP and NAD(H) levels were measured by CellTiterGlo and NAD/NADH-Glo assays (Promega). Readings were normalized to cell numbers measured with Casy (OMNI Life Sciences) on a mirror plate.
Data analysis and visualization
Exploratory data analysis and visualizations were performed in R-project version 3.6.0 (47) with RStudio IDE version 1.2.1578, ggplot2 (3.3.0), dplyr (0.8.5), readr (1.3.1).
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Hediger, M. A., Clémençon, B., Burrier, R. E. & Bruford, E. A. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol. Asp. Med. 34, 95–107 (2013).
Perland, E. & Fredriksson, R. Classification systems of secondary active transporters. Trends Pharmacol. Sci. 38, 305–315 (2017).
Meixner, E. et al. A substrate‐based ontology for human solute carriers. Mol. Syst. Biol. 16, e9652 (2020).
César-Razquin, A. et al. A call for systematic research on solute carriers. Cell 162, 478–487 (2015).
Dixon, S. J., Costanzo, M., Baryshnikova, A., Andrews, B. & Boone, C. Systematic mapping of genetic interaction networks. Annu. Rev. Genet. 43, 601–625 (2009).
Costanzo, M. et al. Global genetic networks and the genotype-to-phenotype relationship. Cell 177, 85–100 (2019).
Domingo, J., Baeza-Centurion, P. & Lehner, B. The causes and consequences of genetic interactions (epistasis). Annu. Rev. Genomics Hum. Genet. 20, 433–460 (2019).
Horlbeck, M. A. et al. Mapping the genetic landscape of human cells. Cell 174, 953–967 (2018).
Najm, F. J. et al. Orthologous CRISPR–Cas9 enzymes for combinatorial genetic screens. Nat. Biotechnol. 36, 179–189 (2017).
DeWeirdt, P. C. et al. Optimization of AsCas12a for combinatorial genetic screens in human cells. Nat Biotechnol. https://doi.org/10.1038/s41587-020-0600-6 (2020).
Gonatopoulos-Pournatzis, T. et al. Genetic interaction mapping and exon-resolution functional genomics with a hybrid Cas9–Cas12a platform. Nat. Biotechnol. 38, 638–648 (2020).
Norman, T. M. et al. Exploring genetic interaction manifolds constructed from rich single-cell phenotypes. Science 365, 786–793 (2019).
Girardi, E. et al. A systematic genetic interaction map of human solute carriers assigns a role to SLC25A51/MCART1 in mitochondrial NAD uptake. Preprint at https://doi.org/10.1101/2020.08.31.275818 (2020).
Bürckstümmer, T. et al. A reversible gene trap collection empowers haploid genetics in human cells. Nat. Methods 10, 965–971 (2013).
Blomen, V. A. et al. Gene essentiality and synthetic lethality in haploid human cells. Science 350, 1092–1096 (2015).
Girardi, E. et al. A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs. Nat. Chem. Biol. 16, 469–478 (2020).
Palmieri, F. The mitochondrial transporter family SLC25: identification, properties and physiopathology. Mol. Asp. Med. 34, 465–484 (2013).
Ruprecht, J. J. & Kunji, E. R. S. The SLC25 mitochondrial carrier family: structure and mechanism. Trends Biochem. Sci. 45, 244–258 (2020).
Kory, N. et al. SFXN1 is a mitochondrial serine transporter required for one-carbon metabolism. Science 362, eaat9528 (2018).
Katsyuba, E., Romani, M., Hofer, D. & Auwerx, J. NAD+ homeostasis in health and disease. Nat. Metab. 2, 9–31 (2020).
Verdin, E. NAD+ in aging, metabolism, and neurodegeneration. Science 350, 1208–1213 (2015).
Yang, H. et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130, 1095–1107 (2007).
Berger, F., Lau, C., Dahlmann, M. & Ziegler, M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J. Biol. Chem. 280, 36334–36341 (2005).
Davila, A. et al. Nicotinamide adenine dinucleotide is transported into mammalian mitochondria. eLife 7, e33246 (2018).
Cambronne, X. A. et al. Biosensor reveals multiple sources for mitochondrial NAD+. Science 352, 1474–1477 (2016).
Todisco, S., Agrimi, G., Castegna, A. & Palmieri, F. Identification of the mitochondrial NAD+ transporter in Saccharomyces cerevisiae. J. Biol. Chem. 281, 1524–1531 (2006).
Palmieri, F. et al. Molecular identification and functional characterization of Arabidopsis thaliana mitochondrial and chloroplastic NAD+ carrier proteins. J. Biol. Chem. 284, 31249–31259 (2009).
VanLinden, M. R. et al. Subcellular distribution of NAD+ between cytosol and mitochondria determines the metabolic profile of human cells. J. Biol. Chem. 290, 27644–27659 (2015).
Mueckler, M. & Thorens, B. The SLC2 (GLUT) family of membrane transporters. Mol. Asp. Med. 34, 121–138 (2013).
Furukawa, J. et al. Functional identification of SLC43A3 as an equilibrative nucleobase transporter involved in purine salvage in mammals. Sci. Rep. 5, 15057 (2015).
Koppula, P., Zhang, Y., Zhuang, L. & Gan, B. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. 38, 12 (2018).
Palmieri, F. & Monné, M. Discoveries, metabolic roles and diseases of mitochondrial carriers: a review. Biochim. Biophys. Acta 1863, 2362–2378 (2016).
Antonicka, H. et al. A high-density human mitochondrial proximity interaction network. Cell Metab. 32, 479–497.e9 (2020).
Wang, T. et al. Identification and characterization of essential genes in the human genome. Science 350, 1096–1101 (2015).
Schaller, L. & Lauschke, V. M. The genetic landscape of the human solute carrier (SLC) transporter superfamily. Hum. Genet. https://doi.org/10.1007/s00439-019-02081-x (2019).
Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
Boulet, A. et al. The mammalian phosphate carrier SLC25A3 is a mitochondrial copper transporter required for cytochrome c oxidase biogenesis. J. Biol. Chem. 293, 1887–1896 (2018).
Seifert, E. L., Ligeti, E., Mayr, J. A., Sondheimer, N. & Hajnóczky, G. The mitochondrial phosphate carrier: role in oxidative metabolism, calcium handling and mitochondrial disease. Biochem. Biophys. Res. Commun. 464, 369–375 (2015).
Santoro, V. et al. SLC25A32 sustains cancer cell proliferation by regulating flavin adenine nucleotide (FAD) metabolism. Oncotarget 11, 801–812 (2020).
Wang, T. et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras. Cell 168, 890–903.e15 (2017).
Dempster, J. M. et al. Extracting biological insights from the project Achilles genome-scale CRISPR screens in cancer cell lines. Preprint at https://doi.org/10.1101/720243 (2019).
AGRIMI, G. et al. Identification of the human mitochondrial S-adenosylmethionine transporter: bacterial expression, reconstitution, functional characterization and tissue distribution. Biochem. J. 379, 183–190 (2004).
Lindhurst, M. J. et al. Knockout of Slc25a19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia. PNAS 103, 15927–15932 (2006).
Kory, N. et al. MCART1/SLC25A51 is required for mitochondrial NAD transport. Sci.Adv. 6, eabe5310 https://doi.org/10.1126/sciadv.abe5310 (2020).
Luongo, T. S. et al. SLC25A51 is a mammalian mitochondrial NAD+ transporter. Nature https://doi.org/10.1038/s41586-020-2741-7 (2020).
Costanzo, M. et al. The genetic landscape of a cell. Science 327, 425–431 (2010).
Rebsamen, M. et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature https://doi.org/10.1038/nature14107 (2015).
Heinz, L. X. et al. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7–9. Nature 581, 316–322 (2020).
Winter, G. E. et al. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat. Chem. Biol. 10, 768–773 (2014).
Sedlyarov, V. et al. The bicarbonate transporter SLC4A7 plays a key role in macrophage phagosome acidification. Cell Host Microbe 23, 766–774 (2018).
Fauster, A. et al. Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking. Cell Death Differ. 26, 1138–1155 (2018).
Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).
Jewison, T. et al. SMPDB 2.0: big improvements to the small molecule pathway database. Nucleic Acids Res. 42, D478–D484 (2014).
Chong, J. et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Res. 46, W486–W494 (2018).
Frezza, C., Cipolat, S. & Scorrano, L. Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat. Protoc. 2, 287–295 (2007).
We are grateful to the ProMet and Biomedical Sequencing (BSF) facilities at CeMM/MUW. We thank the members of the Superti-Furga and Menche groups for critical discussions. We acknowledge support by the Austrian Academy of Sciences, the European Research Council (ERC AdG 695214, E.G., G.F., M.R., ERC 677006, A.B.) and the Austrian Science Fund (FWF P29250-B30 VITRA, E.G., J.K., G.F.; FWF DK W1212, B.A., A.B.).
The authors declare no competing interests.
Peer review information Nature Communications thanks Jun Yoshino and other, anonymous, reviewers for their contributions to the peer review of this work. Peer review reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Girardi, E., Agrimi, G., Goldmann, U. et al. Epistasis-driven identification of SLC25A51 as a regulator of human mitochondrial NAD import. Nat Commun 11, 6145 (2020). https://doi.org/10.1038/s41467-020-19871-x
This article is cited by
Combinatorial GxGxE CRISPR screen identifies SLC25A39 in mitochondrial glutathione transport linking iron homeostasis to OXPHOS
Nature Communications (2022)
Nature Reviews Molecular Cell Biology (2022)
Nature Metabolism (2022)
Cell Discovery (2022)
Cellular and Molecular Life Sciences (2022)